By Turna Ray

CYP2C19 alleles ⢀ which various studies have shown to limit response to the anti-platelet drug Plavix in carriers of the polymorphisms ⢀ did not have the same impact on patients' ability to metabolize the drug in a study published in the New England Journal of Medicine last week.

The authors of the study said they believe the data raises doubts on the clinical utility of genotyping for CYP2C19 loss-of-function alleles as a way to direct Plavix therapy in patients with acute coronary syndrome and atrial fibrillation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: oral microbiomes of dogs and their owners, Plasmodium vivax population structure, and more.

The American Society of Human Genetics has issued a position statement on genetic testing of children.

The White House seeks to update how biotechnology products are regulated.

Team science leads some researchers to get lost in the shuffle, the Chronicle of Higher Education reports.